JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akhtar, M. S.
Right arrow Articles by Imran, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akhtar, M. S.
Right arrow Articles by Imran, M. B.

Antimicrobial Peptide 99mTc-Ubiquicidin 29–41 as Human Infection-Imaging Agent: Clinical Trial

Muhammad Saeed Akhtar, MBBS, MSc1, Aitzaz Qaisar, MBBS, MSc1, Javaid Irfanullah, MBBS, MSc1, Javaid Iqbal, MBBS, MSc1, Bashar Khan, MSc2, Mustansar Jehangir, PhD2, Muhammad Afzal Nadeem, MPhil1, Muhammad Aleem Khan, MBBS, MSc1, Muhammad Shahzad Afzal, MBBS, MSc1, Ikram ul-Haq, MBBS, MPhil3 and Muhammad Babar Imran, MBBS, PhD1

1 Punjab Institute of Nuclear Medicine, Faisalabad, Pakistan
2 Isotope Production Division, Pakistan Institute of Nuclear Science and Technology, Islamabad, Pakistan; Surgical Unit 3, Allied Hospital, Faisalabad, Pakistan
3 Department of Clinical Pathology, Allied Hospital, Faisalabad, Pakistan



View larger version (40K):

[in a new window]
  		FIGURE 1. Processing page for calculation of T/NT.

 


View larger version (26K):

[in a new window]
  		FIGURE 2. Anterior whole-body image at 30 min after tracer injection showing kidneys (dotted arrow), liver (solid arrow), and urinary bladder (ball arrow).

 


View larger version (21K):

[in a new window]
  		FIGURE 3. Scintigraphic biodistribution of 99mTc-UBI 29–41. Percentage injected dose (%ID) data for organs are mean of 3 data points, taking whole-body counts as 100% of injected dose at each interval.

 


View larger version (28K):

[in a new window]
  		FIGURE 4. Positive 99mTc-UBI 29–41 scintigraphy findings in patient with infection in medial aspect of right hand. Markedly greater focal tracer accumulation is seen on side with infection (arrows) than on normal contralateral side. Tracer uptake is maximal on image obtained at 30 min.

 


View larger version (88K):

[in a new window]
  		FIGURE 5. (A) Focally increased 99mTc-MDP uptake during skeletal phase in upper femoral shaft (solid arrow) and tip of hip prosthesis (dotted arrow). (B–D) 99mTc-UBI 29–41 scintigrams obtained at 30 min (B), 60 min (C), and 120 min (D) show no tracer uptake to rule out infection at these sites. Urinary bladder is shielded in image obtained at 120 min.

 


View larger version (27K):

[in a new window]
  		FIGURE 6. T/NTs at different intervals in 18 patients examined with infection imaging.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.